Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-21), Beijing Sunho Pharmaceutical Co's Beta is 1.0636.
Beijing Sunho Pharmaceutical Co (BJSE:920017) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Beijing Sunho Pharmaceutical Co Beta Related Terms
Beijing Sunho Pharmaceutical Co Beta Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Sunho Pharmaceutical Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Sunho Pharmaceutical Co Beta vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Sunho Pharmaceutical Co's Beta distribution charts can be found below:
* The bar in red indicates where Beijing Sunho Pharmaceutical Co's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Beijing Sunho Pharmaceutical Co (BJSE:920017) has a Beta of 1.0636 as of Sep. 21, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Beijing Sunho Pharmaceutical Co and its competitors.
Is Beijing Sunho Pharmaceutical Co's Beta too high?
Beijing Sunho Pharmaceutical Co's current Beta is 1.0636. Overall, Beijing Sunho Pharmaceutical Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beijing Sunho Pharmaceutical Co's Beta compare to ZTS?
Beijing Sunho Pharmaceutical Co's Beta of 1.0636 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Beijing Sunho Pharmaceutical Co and its competitors. Beijing Sunho Pharmaceutical Co's current Beta is 1.0636. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Sunho Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Sunho Pharmaceutical Co (BJSE:920017) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.19, compared to a current price of ¥15.67 — trading 3.2% above its estimated fair value. The current Beta is 1.0636. Beijing Sunho Pharmaceutical Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Beijing Sunho Pharmaceutical Co (BJSE:920017), the current Beta is 1.0636 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Sunho Pharmaceutical Co (BJSE:920017) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Sunho Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.67 is trading 3.2% above its estimated GF Value™ of ¥15.19.
GuruFocus considers Beijing Sunho Pharmaceutical Co to be Fairly Valued.
Key valuation signals for BJSE:920017:
Beta: 1.0636
GF Value™: ¥15.19 vs. price of ¥15.67 (3.2% above fair value)
No single metric tells the full story. See the BJSE:920017 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Sunho Pharmaceutical Co Ltd engages in the research and development, production, and sales of pharmaceutical preparations while providing CMC/CMO integrated services for pharmaceutical preparation manufacturers and drug R&D enterprises. The company produces small-volume injections, freeze-dried powder injections, hard capsules, tablets, and other products. The company's main products included: compound digestive enzyme capsules, piracetam (small injection and powder injection), and oxalic acid acetate.
80GF Score
Get the complete analysis for BJSE:920017
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920017 has been successfully added to your 
